3Freed MI,West WM,Viberti G.Rosiglitazone reduces urinary albumin excretion in type 2[J].Diabetes 被引量：1
4Goldstein BJ.Insulin resistance as the core defect in type 2 diabetes mellitus[J].Am J Cardiol,2002,90:3G-10G 被引量：1
5Walker AB,Chattington PD,Buckingham RE,et al.The thia-zolidinedione rosiglitazone lowers blood pressure and protects against impaiment of endothelial function in Zucker fatty rats[J].Diabetes,1999,48:1448-1453 被引量：1
6Haffner SM.Efeect of rosiglitazone treatment on nontraditional markers cardiovascular disease in patients with type 2 diabetes mellitus[J].Circulation,2002,106(6):679-684 被引量：1
1[1]Harris Mi,Flegal KM,Cowie CC,Eberhardt MS,Goldstein DE,Little RR,Wiedmeyer HM,Byrd-Holt DD:Prevalence of diabetes,impaired fasting gluccse,and impaired glucose tolerance in U.S,adults:the Third National Health and Nutrition Examination Survey,1998-94.Diabetes care,1998,21:518～524, 被引量：1
2[2]Meneilly GS,Elliott T,Tessier D,Hards L,Tildesiey H:NIDDM in the elderly.Diabetes Care 19:1320～1325.1996 被引量：1
3[3]Meneilly GS,Tessier D:Diabetes in the elderly.Diabet Med,1995,12:949～960. 被引量：1
4[4]Spiegelman BM.PPAR-gamma:adipogenic regulator and thiazolidinedione receptor.Diabetes 1998,47:507～514. 被引量：1
6[6]Jones NP,Mather R,Owen S,et al.Long-term efficacy of rosiglitazone as monotherapy or in combination with metformin.Diabetologia 2000;43(Supplement 1):A192. 被引量：1
